Not Signed In -
Rituximab |
Rituxan |
Image:Rituximab.png Rituximab Systematic (IUPAC) name Chimeric murine/human monoclonal anti-CD20 antibody Identifiers CAS number 174722-31-7 ATC code L01XC02 PubChem ? DrugBank BTD00014 Chemical data Formula C6416H9874N1688O1987S44 Mol. weight 143859.7 g/mol Pharmacokinetic data Bioavailability ? Metabolism ? Half life ? Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status Routes ? Rituximab, ...
Wikipedia - [full article]
Rituximab Clinical Trials
- Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00193479 - Active, not recruiting
Non-Hodgkins Lymphoma
- Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
ClinicalTrials.gov Identifier: NCT00003356 - Active, not recruiting
Lymphoma
- Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00250861 - Active, not recruiting
Non-Hodgkin's Lymphoma
- Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00242996 - Active, not recruiting
Lymphoma
- Efficacy and Safety Study of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
ClinicalTrials.gov Identifier: NCT00074438 - Active, not recruiting
Rheumatoid Arthritis
- A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate
ClinicalTrials.gov Identifier: NCT00266227 - Active, not recruiting
Rheumatoid Arthritis
- Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
ClinicalTrials.gov Identifier: NCT00435955 - Active, not recruiting
Follicular Lymphoma
- A Study of Apomab in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy
ClinicalTrials.gov Identifier: NCT00517049 - Recruiting
Lymphoma, Non-Hodgkin
- A Study to Evaluate Rituximab in Adults with Relapsing Remitting Multiple Multiple Sclerosis
ClinicalTrials.gov Identifier: NCT00097188 - Active, not recruiting
Multiple Sclerosis
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
ClinicalTrials.gov Identifier: NCT00577161 - Recruiting
Non-Hodgkin's Lymphoma
- A Study to Evaluate the Safety and Efficacy of Rituximab in Adults with Primary Progressive Multiple Sclerosis
ClinicalTrials.gov Identifier: NCT00087529 - Active, not recruiting
Multiple Sclerosis
- Combination Chemotherapy Plus Interferon alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
ClinicalTrials.gov Identifier: NCT00004039 - Active, not recruiting
Lymphoma
- ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients with Diffuse Large B-Cell Lymphoma and Age-Adjusted IPI of 1
ClinicalTrials.gov Identifier: NCT00140595 - Recruiting
Diffuse Large-Cell Lymphoma
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
ClinicalTrials.gov Identifier: NCT00071396 - Active, not recruiting
Chronic Lymphocytic Leukemia
- A Study to Evaluate the Efficacy and Safety of Rituximab in Patients with Severe Systemic Lupus Erythematosus (SLE)
ClinicalTrials.gov Identifier: NCT00137969 - Active, not recruiting
Lupus Erythematosus, Systemic
- Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
ClinicalTrials.gov Identifier: NCT00151320 - Active, not recruiting
Non-Hodgkin''s Lymphoma
- Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00060346 - Active, not recruiting
Waldenstrom's Macroglobulinemia
- ACVBP Plus Rituximab in Patients Aged from 18 to 59 Years with High-Risk Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00144807 - Active, not recruiting
Diffuse Large Cell Lymphoma
- Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00004889 - Active, not recruiting
Waldenstrom's Macroglobulinemia
- Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov Identifier: NCT00086203 - Active, not recruiting
Chronic Lymphocytic Leukemia
- A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
ClinicalTrials.gov Identifier: NCT00363636 - Recruiting
Lymphoma, Non-Hodgkin's
- Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00005959 - Active, not recruiting
Lymphoma
- CC-5013 and Rituximab in Waldenstrom''s Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00142168 - Active, not recruiting
Waldenstrom''s Macroglobulinemia
- Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00007865 - Active, not recruiting
adult non-Hodgkin's lymphoma
- Rituximab+Standard CHOP Vs Rituximab+Bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)
ClinicalTrials.gov Identifier: NCT00147121 - Active, not recruiting
Untreated stage III/IV low-grade B-cell lymphoma
- Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-Cell Lymphoma, a Form of Non-Hodgkin’s Lymphoma
ClinicalTrials.gov Identifier: NCT00308087 - Recruiting
Lymphoma, Follicular
- Study to Evaluate the Efficacy of Rituximab in Combination with Low-Dose Radiotherapy in Patients with Relapsed Non-Hodgkin''s Lymphoma
ClinicalTrials.gov Identifier: NCT00147953 - Recruiting
Non-Hodgkin''s Lymphoma
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00001337 - Recruiting
Non Hodgkin's Lymphoma
- Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00072007 - Active, not recruiting
B-cell Chronic Lymphocytic Leukemia; refractory chronic lymphocytic leukemia; stage II chronic lymphocytic leukemia; ...
- Oblimersen and Rituximab in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00054639 - Active, not recruiting
adult non-Hodgkin's lymphoma
- VELCADE® (bortezomib) with Rituximab in Subjects with Relapsed or Refractory Indolent B-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00085696 - Active, not recruiting
B-Cell Lymphoma; Follicular Lymphoma; Marginal Lymphoma
- Genasense™ (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects with Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00078234 - Active, not recruiting
Chronic Lymphocytic Leukemia
- Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin''s Lymphoma
ClinicalTrials.gov Identifier: NCT00117156 - Active, not recruiting
Lymphoma, Non-Hodgkin; MALT Lymphoma
- Rituximab to Treat Stiff Person Syndrome
ClinicalTrials.gov Identifier: NCT00091897 - Active, not recruiting
Stiff Person Syndrome
- Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
ClinicalTrials.gov Identifier: NCT00005652 - Active, not recruiting
Purpura, Thrombocytopenic, Idiopathic
- Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00096044 - Active, not recruiting
refractory chronic lymphocytic leukemia
- Diffuse Large B Cell Lymphoma of the Adult: Randomisation Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
ClinicalTrials.gov Identifier: NCT00561379 - Recruiting
Lymphoma, Large-Cell, Diffuse
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00004179 - Active, not recruiting
grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma
- Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
ClinicalTrials.gov Identifier: NCT00104299 - Recruiting
Vasculitis; Wegener's Granulomatosis
- Thalidomide and Rituximab in Waldenstrom''s Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00142116 - Active, not recruiting
Waldenstrom''s Macroglobulinemia; Lymphoplasmacytic lymphoma
- Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00010192 - Active, not recruiting
adult acute lymphoblastic leukemia; adult non-Hodgkin's lymphoma
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin''s Lymphoma That Has Relapsed After Previous Rituximab Treatment
ClinicalTrials.gov Identifier: NCT00238238 - Recruiting
Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma
- Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00062296 - Active, not recruiting
adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia
- Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
ClinicalTrials.gov Identifier: NCT00049413 - Active, not recruiting
adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia
- Rituximab and ABVD for Hodgkin's Patients
ClinicalTrials.gov Identifier: NCT00504504 - Active, not recruiting
Lymphoma
- Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
ClinicalTrials.gov Identifier: NCT00029107 - Recruiting
Hepatitis C; Vasculitis
- Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance versus Dose-Adjusted EPOCH-Rituximab-Bortezomib followed by Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and Prot
ClinicalTrials.gov Identifier: NCT00114738 - Recruiting
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00006708 - Active, not recruiting
recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma; recurrent adult diffuse large cell lymphoma
- A Study of CC-5013 and Rituximab in the Treatment of Relapsed MCL.
ClinicalTrials.gov Identifier: NCT00294632 - Active, not recruiting
Lymphoma
- Cyclophosphamide With or Without Rituximab and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00028665 - Active, not recruiting
adult non-Hodgkin's lymphoma
- Flavopiridol, Fludarabine, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00058227 - Active, not recruiting
adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; Hairy Cell Leukemia
- Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00089115 - Active, not recruiting
grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma
- Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00086775 - Active, not recruiting
refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
- Safety Study of Rituximab(Rituxan®) in Chronic Urticaria
ClinicalTrials.gov Identifier: NCT00216762 - Recruiting
Urticaria
- Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
ClinicalTrials.gov Identifier: NCT00126191 - Recruiting
Burkitt Lymphoma; Non-Hodgkins Lymphoma; Atypical Burkitt Lymphoma
- Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00052923 - Active, not recruiting
recurrent adult diffuse large cell lymphoma
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.gov Identifier: NCT00143065 - Active, not recruiting
Lymphoma, Small Lymphocytic; Lymphocytic Leukemia, Chronic
- Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00093769 - Active, not recruiting
grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma; marginal zone lymphoma
- Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
ClinicalTrials.gov Identifier: NCT00452374 - Active, not recruiting
Leukemia
- Rituximab and Galiximab in Treating Patients with Stage II, Stage III, Or Stage IV Non-Hodgkin''s Lymphoma
ClinicalTrials.gov Identifier: NCT00117975 - Active, not recruiting
grade 1 follicular lymphoma; grade 2 follicular lymphoma; grade 3 follicular lymphoma
- Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy
ClinicalTrials.gov Identifier: NCT00003757 - Active, not recruiting
refractory hairy cell leukemia; progressive hairy cell leukemia, initial treatment
- A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
ClinicalTrials.gov Identifier: NCT00221325 - Recruiting
Central nervous system lymphoma; Intraocular Lymphoma
- Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00005631 - Active, not recruiting
recurrent adult immunoblastic large cell lymphoma; recurrent adult diffuse large cell lymphoma; anaplastic large cell lymphoma
- Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
ClinicalTrials.gov Identifier: NCT00251277 - Recruiting
Thrombotic Thombocytopenic Purpura; TTP; Hematology
- Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00060164 - Active, not recruiting
recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma
- Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
ClinicalTrials.gov Identifier: NCT00003658 - Active, not recruiting
adult non-Hodgkin's lymphoma; Chronic Lymphocytic Leukemia; indolent or aggressive adult non-Hodgkin's lymphoma
- Rituximab for the Treatment of Dermatomyositis and Polymyositis
ClinicalTrials.gov Identifier: NCT00106184 - Recruiting
Myositis; Dermatomyositis; Polymyositis
- ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov Identifier: NCT00140660 - Recruiting
Diffuse Large Cell Lymphoma
- Rituximab With or Without Interleukin-12 in Treating Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00026182 - Active, not recruiting
Waldenstrom's Macroglobulinemia; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; ...
- Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00028717 - Active, not recruiting
adult diffuse large cell lymphoma; adult non-Hodgkin's lymphoma; grade 3 follicular lymphoma; Mantle Cell Lymphoma
- EPOCH-Rituximab to Treat non-Hodgkin's Lymphoma in Patients with HIV Infection
ClinicalTrials.gov Identifier: NCT00006436 - Recruiting
AIDS Related Lymphoma; HIV Infection
- CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00109967 - Recruiting
recurrent mantle cell lymphoma
- Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00086944 - Active, not recruiting
recurrent adult diffuse large cell lymphoma; recurrent mantle cell lymphoma; recurrent grade 3 follicular lymphoma
- RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
ClinicalTrials.gov Identifier: NCT00259974 - Recruiting
Polyneuropathy Associated With Anti-MAG IgM Gammopathy
- A Study of Rituximab versus Iodine I 131 Tositumomab Therapy for Patients with Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00078598 - Recruiting
Non-Hodgkin's Lymphoma
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00005589 - Active, not recruiting
recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma
- Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00265915 - Active, not recruiting
Leukemia
- R-ICE Versus R-DHAP in Patients Aged 18-65 with Relapse Diffuse Large B Cell Lymphoma.
ClinicalTrials.gov Identifier: NCT00137995 - Recruiting
Lymphoma, Large-Cell, Diffuse
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00281931 - Active, not recruiting
Leukemia
- Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
ClinicalTrials.gov Identifier: NCT00577993 - Active, not recruiting
Lymphoma
- Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00250926 - Active, not recruiting
Waldenstrom's Macroglobulinemia
- Combination Chemotherapy Plus Rituximab in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00019253 - Active, not recruiting
Lymphoma
- Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00343447 - Active, not recruiting
Leukemia
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
ClinicalTrials.gov Identifier: NCT00384150 - Enrolling by invitation
Non-Hodgkin Lymphoma
- Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
ClinicalTrials.gov Identifier: NCT00416923 - Active, not recruiting
Lymphoma; Metastatic Cancer
- Rituximab Therapy for Steroid-Refractory Chronic Graft Vs. Host Disease
ClinicalTrials.gov Identifier: NCT00136396 - Active, not recruiting
Steroid-refractory Chronic Graft vs. Host Disease; GVHD
- Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00281918 - Active, not recruiting
Leukemia
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00337246 - Active, not recruiting
Leukemia
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
ClinicalTrials.gov Identifier: NCT00416819 - Active, not recruiting
Lymphoma
- Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00227695 - Active, not recruiting
Lymphoma
- Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00193440 - Active, not recruiting
Non-Hodgkins Lymphoma
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00436904 - Active, not recruiting
Leukemia
- CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00574730 - Active, not recruiting
Non-Hodgkins Lymphoma
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia
ClinicalTrials.gov Identifier: NCT00003659 - Active, not recruiting
stage II chronic lymphocytic leukemia; stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
ClinicalTrials.gov Identifier: NCT00579592 - Active, not recruiting
Acute Rejection; Renal Transplantation
- Etoposide and G-CSF With or Without Rituximab in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00274794 - Active, not recruiting
Lymphoma
- Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00006669 - Active, not recruiting
recurrent adult diffuse small cleaved cell lymphoma; recurrent grade III follicular large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; ...
- Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin''s Lymphoma
ClinicalTrials.gov Identifier: NCT00248534 - Recruiting
Primary Central Nervous System Lymphoma
- A Phase II Study of Rituximab Combined with CHOP in T-Cell Angio-Immunoblastic Lymphoma
ClinicalTrials.gov Identifier: NCT00169156 - Recruiting
Untreated T-cell angioimmunoblastic lymphoma
- Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
ClinicalTrials.gov Identifier: NCT00066469 - Recruiting
post-transplant lymphoproliferative disorder
email this page
print this page
bookmark this page
feedback on this page
